Tocagen plummets on phase 3 data for glioma therapy

Tocagen’s brain tumour candidate gets PRIME designation

An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.

Tocagen aims for IPO to fund brain cancer trial

Brain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this year, after mixed success for recent market launches.